Filing Flows

Filing Flows › Companies › Organogenesis Holdings › Cash flow

Organogenesis Holdings cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$20.1M in Q3 2026 · −$64K over twelve months

Operating cash flow−$18.6M
Capital spending−$1.5M
Free cash flow−$20.1M

Analysis

In Q3 2026, Organogenesis Holdings generated −$18.6M of operating cash flow and spent $1.5M on capital projects, leaving free cash flow of −$20.1M. That is $20.9M less than in Q3 2025 ($844K).

Over the twelve months to Sep 30, 2026, operating cash flow was $10.3M; the largest uses were other financing ($26.9M), net borrowing (+) / repaid (−) ($10.9M), capital spending ($10.4M); besides operations, cash came from other investing ($3.6M); the cash balance fell by $37.4M.

Operating cash flow was −$18.6M against net income of −$29.6M. The largest differences: payables −$5.5M, receivables +$4.1M, depreciation & amortization +$3.9M.

Free cash flow

Organogenesis Holdings: free cash flow by quarterOrganogenesis Holdings: free cash flow by quarter$7.6MQ4 2024−$23.6MQ1 2025−$36.5MQ2 2025$844KQ3 2025$34.8MQ4 2025$18.0MQ1 2026−$32.8MQ2 2026−$20.1MQ3 2026
Operating cash flow less capital spending.
Organogenesis Holdings: operating cash flow against capital spendingOrganogenesis Holdings: operating cash flow against capital spendingOperating cash flowCapital spending$10.9M$3.4MQ4 2024−$19.9M$3.6MQ1 2025−$32.9M$3.6MQ2 2025$3.1M$2.2MQ3 2025$39.4M$4.7MQ4 2025$21.1M$3.1MQ1 2026−$31.7M$1.1MQ2 2026−$18.6M$1.5MQ3 2026
Latest (Q3 2026): Operating cash flow −$18.6M, Capital spending $1.5M.

Capital allocation, year by year

Organogenesis Holdings: where the cash came from (up) and went (down), by fiscal yearOrganogenesis Holdings: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingBuybacksFY2021: Operating cash flow $62.0MFY2021: Net borrowing −$2.6MFY2021: Shares issued $2.2MFY2021: Capital spending −$31.2M$64.2MFY2021FY2022: Operating cash flow $24.9MFY2022: Net borrowing −$3.0MFY2022: Shares issued $2.1MFY2022: Capital spending −$33.9M$26.9MFY2022FY2023: Operating cash flow $30.9MFY2023: Net borrowing −$5.2MFY2023: Capital spending −$24.4M$30.9MFY2023FY2024: Operating cash flow $14.2MFY2024: Net borrowing −$67.6MFY2024: Shares issued $122MFY2024: Capital spending −$10.0MFY2024: Buybacks −$25.5M$136MFY2024FY2025: Operating cash flow −$10.3MFY2025: Net borrowing −$1.2MFY2025: Shares issued $157KFY2025: Capital spending −$14.2M$157KFY2025
Over these 5 years operating cash flow totalled $122M; the largest uses were capital spending ($114M) and net borrowing ($79.6M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$21.3M
Debtnone
Net cash$21.3M
Cash runway3 months

Organogenesis Holdings is burning cash: its operations consume cash, a free cash flow of −$80.2M a year at the current rate against $21.3M of cash and investments: a runway of about 3 months before any new financing.

Where the cash came from and went

Organogenesis Holdings: sources (+) and uses (−) of cash, Q3 2026Organogenesis Holdings: sources (+) and uses (−) of cash, Q3 2026Cash drawn (+) / kept (−)$19.9MOperating cash flow−$18.6MOther investing$3.8MOther financing−$3.0MCapital spending−$1.5MNet borrowing (+) / repaid (−)−$410KAsset & business sales−$138KTaxes on employees’ shares$1K
Organogenesis Holdings: sources (+) and uses (−) of cash, TTM to Q3 2026Organogenesis Holdings: sources (+) and uses (−) of cash, TTM to Q3 2026Cash drawn (+) / kept (−)$37.4MOther financing−$26.9MNet borrowing (+) / repaid (−)−$10.9MCapital spending−$10.4MOperating cash flow$10.3MOther investing$3.6MTaxes on employees’ shares−$3.1M

From profit to cash

Organogenesis Holdings: net income to operating cash flow, Q3 2026Organogenesis Holdings: net income to operating cash flow, Q3 2026Net income−$29.6MDepreciation & amortization$3.9MStock-based pay$2.8MGains on disposals$328KReceivables$4.1MInventory−$2.9MPayables−$5.5MPrepaid and other assets$2.1MOther liabilities−$404KOperating cash flow−$18.6M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q1 2025111105102114
Q4 202477797877

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$18.6M−$1.5M−$410K—$19.9M−$20.1M
Q2 2026−$31.7M−$1.1M−$348K—$45.3M−$32.8M
Q1 2026$21.1M−$3.1M−$9.8M—$2.2M$18.0M
Q4 2025$39.4M−$4.7M−$302K$2K−$30.0M$34.8M
Q3 2025$3.1M−$2.2M−$296K$130K$9.4M$844K
Q2 2025−$32.9M−$3.6M−$288K—$36.8M−$36.5M
Q1 2025−$19.9M−$3.6M−$285K$25K$25.6M−$23.6M
Q4 2024$10.9M−$3.4M−$62.6M$1.1M−$41.2M$7.6M

Organogenesis Holdings: income statement and cash flow

Organogenesis Holdings, Q3 2026: revenue $45.5M (-70% year over year), operating margin -64.9%. The chart follows the revenue to costs, profit and cash.

Organogenesis Holdings: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.